SCHEDULE: Linden Entities Report Stake in Translational Development Acquisition Corp.
Schedule 13G Filing
Linden Capital L.P. and affiliated entities report beneficial ownership of 950,000 Class A Ordinary Shares, representing approximately 5.5% of the outstanding shares of Translational Development Acquisition Corp.
Summary
- Linden Capital L.P., along with Linden GP LLC, Linden Advisors LP, and Siu Min Wong, have filed a Schedule 13G.
- The filing indicates beneficial ownership of 950,000 Class A Ordinary Shares of Translational Development Acquisition Corp.
- This ownership represents approximately 5.5% of the outstanding shares for Linden Advisors LP and Siu Min Wong.
- Linden GP LLC and Linden Capital L.P. hold approximately 5.3% of the outstanding shares.
- The shares are held through Linden Capital (913,482 shares) and separately managed accounts (36,518 shares).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership without specific financial performance data or strategic announcements.
Positives
- Significant stake reported, indicating investor confidence or strategic interest in Translational Development Acquisition Corp.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding future performance.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant beneficial ownership of public companies, often indicating institutional or activist investor interest. This filing by Linden entities suggests a notable position in Translational Development Acquisition Corp.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding significant ownership stakes, which can influence market perception and potential future corporate actions.
Key Dates
| Date | Description |
|---|---|
| 2019-06-10 | Date of Power of Attorney for Siu Min Wong. |
| 2019-06-19 | Date of prior Schedule 13G filing by Linden Capital L.P. regarding Haymaker Acquisition Corp II. |
| 2026-05-27 | Date of Event Which Requires Filing of this Statement (Schedule 13G filing date). |
| 2026-06-02 | Date of Joint Filing Agreement and signatures on Schedule 13G. |
Keywords
Schedule 13G, Translational Development Acquisition Corp., Linden Capital L.P., Linden Advisors LP, Siu Min Wong, Class A Ordinary Shares, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.